Supernus has boosted its position in central nervous system therapies with a $400 million deal to acquire Adamas Pharma that will add two approved Parkinson's disease therapies to its stabl
Supernus Pharma has two phase III trials showing its attention-deficit hyperactivity disorder (ADHD) drug SPN-812 met its objectives, but still saw its shares fall as investors digested the
